Biotech | May 11, 2022
New nirsevimab data analyses reinforce efficacy against RSV
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Go-ahead for pivotal clinical trial which is expected to commence by March
Narayanan to lead SeQuent through next phase of consolidation and growth
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
